Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02213848
Other study ID # Calcium RNMB
Secondary ID
Status Completed
Phase N/A
First received August 4, 2014
Last updated June 29, 2015
Start date August 2014
Est. completion date October 2014

Study information

Verified date August 2014
Source Seoul National University Hospital
Contact n/a
Is FDA regulated No
Health authority Korea: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effect of calcium chloride against residual neuromuscular blockade at the end of general anesthesia


Description:

During general anesthesia, neuromuscular blocking agent is administered to facilitate endotracheal intubation and the view of operative field. The neuromuscular blockade should be reversed at the end of anesthesia to recover spontaneous breathing of the patient.

Residual neuromuscular blockade (RNMB) is defined as train of-four ratio < 0.9. RNMB is a risk factor for postoperative pulmonary complication and increases postoperative mortality. Neostigmine is acetylcholinesterase inhibitor routinely used at the end of anesthesia to prevent RNMB. A meta-analysis, however, showed that 40 percent of patients who received intermediate-acting neuromuscular blocking agent during anesthesia showed RNMB in PACU.

Calcium triggers the release of acetylcholine from the motor nerve terminal and enhances excitation-contraction coupling in muscle. Increasing calcium concentrations decreased the sensitivity to dTc and pancuronium in an animal muscle-nerve model. The effect of calcium chloride on residual neuromuscular blockade is not studied yet.

The purpose of this study is to evaluate the effect of calcium chloride on residual neuromuscular blockade at the end of general anesthesia


Recruitment information / eligibility

Status Completed
Enrollment 58
Est. completion date October 2014
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- 18-65 yr

- Body mass index 15.0-25.0 kg/m2

- American Society of Anesthesiologists physical status I-III

- Scheduled for elective surgery with an expected duration of more than 60 min under general anesthesia with endotracheal intubation

Exclusion Criteria:

- Suspected difficulty airway

- Bronchial asthma, chronic obstructive pulmonary disease

- Neuromuscular disease

- Hepatic or renal dysfunction.

- Taking medications that might influence the effect of neuromuscular blocking agents

- Allergy to the medication that used in this trial

- Pregnant, or breastfeeding state

- Suspected malignant hyperthermia

- Contraindication to the medication that used in this trial

- Hypercalcemia

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Calcium
Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
control
In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered

Locations

Country Name City State
Korea, Republic of Seoul National University Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Seoul National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to train of-four ratio of 0.9. Train of-four will be measured using acceleromyograph. At 10 minutes (expected aeverage) after the surgery No
Secondary Train of-four ratio Train of-four will be measured using accelerography. At 5, 10, 20 minutes after the administration of reversal drug No
Secondary Length of PACU stay At 60 minutes (expected average) after the surgery No
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04619225 - Cardiac Output and Recovery Time N/A
Recruiting NCT05992090 - Neuromuscular Blockade Monitoring Using Kine-myography vs Electromyography.
Completed NCT02146859 - Predictor of Residual Neuromuscular Blockade in Recovery Room After General Anesthesia
Completed NCT03585400 - Validation of the REPS Prediction Tool
Terminated NCT01678625 - Electromyographic Assessment of Onset and Recovery of Neuromuscular Blockade
Completed NCT03417804 - Incidence of Postoperative Residual Neuromuscular Blockade in Portugal
Completed NCT03111082 - Incidence of Postoperative Neuromuscular Blockade in Post-Anesthesia Care Unit at Parkland Hospital: Does Size Matter?
Completed NCT04244266 - Observational Study in Bariatric Surgery
Completed NCT02939911 - Residual Neuromuscular Blockade in Pediatric Anesthesia
Completed NCT02660398 - Incidence and Severity of Residual Neuromuscular Blockade Phase 4
Completed NCT03920670 - Comparison of the ToFscan and TetraGraph During Recovery of Neuromuscular Function in the Post Anesthesia Care Unit N/A
Completed NCT01837498 - Reversal of Neuromuscular Blockade in Thoracic Surgical Patients
Completed NCT04352140 - Electromyographic and Acceleromyographic Monitoring in Restricted Arm Movement Surgical Setting N/A
Completed NCT04352127 - Visual and Electromyography Assessments in Response to Train-of-Four Stimulation of the Ulnar Nerve N/A
Completed NCT04312256 - Thumb vs Great Toe Recovery N/A
Withdrawn NCT03574337 - Residual Neuromuscular Blockade in Cardiac Surgery Patients Phase 4